Kenshi Suzuki, MD, PhD, head of Myeloma and AL Amyloidosis
Unit, Japanese Red Cross Medical Center, said, 'The results of TOURMALINE-MM1, a global Phase 3 clinical trial, demonstrated that the all-oral triplet regimen containing ixazomib, lenalidomide and dexamethasone significantly extended the PFS in patients with relapsed or refractory multiple myeloma, with a manageable safety profile.
The most common forms of amyloidosis include systemic AL amyloidosis
(formerly primary amyloidosis), systemic AA amyloidosis (formerly secondary amyloidosis), systemic wild-type ATTR amyloidosis (formerly age-related or senile systemic amyloidosis), systemic hereditary ATTR amyloidosis (formerly familial amyloid polyneuropathy), and localized AL amyloidosis
This is the first proteasome inhibitor and first investigational therapy for AL amyloidosis
to receive Breakthrough Therapy designation.
Odiick's commitment to bettering other peoples' lives was recognized by fans, who gathered outside Vancouver General Hospital to show their respect when Odjick made it known through the Canucks website that he had been diagnosed with AL amyloidosis
, a rare terminal disease.
Cardiac involvement is common in AL amyloidosis
and is associated with various treatment options and prognoses.
Primary AL amyloidosis
has clonal B-cell dyscrasia, including multiple myelomas, B-cell lymphoma, Waldenstrom macroglobulinemia, or another plasma cell neoplasia.
Approximately 4,500 people in the UK are diagnosed with Myeloma while 500 to 600 people in the UK are diagnosed with AL amyloidosis
but treatment for both conditions is the same.
Two global phase 3 trials, TOURMALINE-MM1, to investigate MLN9708 in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma and TOURMALINE-AL1, to investigate MLN9708 plus dexamethasone in patients with relapsed or refractory light chain AL amyloidosis
were initiated in 2012.
In a retrospective study of 19 patients with AL amyloidosis
and 20 with AA amyloidosis, which required dialysis and were followed up after approximately 35 months, 15 (79 % ) with AL and 3 patients (15 %) with AA amyloidosis died10.
Outcome in systemic AL amyloidosis
in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Primary AL amyloidosis
is a protein conformation disorder associated with clonal plasma cell dyscrasia.
Donald was diagnosed with the disease AL amyloidosis
, where an abnormal protein builds up in organs, such as the kidneys and spleen, causing damage.